Information Analysis (OTCMKTS:IAIC – Get Free Report) and SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership.
Profitability
This table compares Information Analysis and SOPHiA GENETICS’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Information Analysis | 3.72% | 18.48% | 9.33% |
| SOPHiA GENETICS | -93.86% | -132.47% | -45.97% |
Insider & Institutional Ownership
31.6% of SOPHiA GENETICS shares are held by institutional investors. 23.8% of Information Analysis shares are held by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Information Analysis | $13.90 million | 0.00 | $410,000.00 | $0.04 | N/A |
| SOPHiA GENETICS | $77.27 million | 8.99 | -$79.00 million | ($1.15) | -7.20 |
Information Analysis has higher earnings, but lower revenue than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Information Analysis, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Information Analysis has a beta of 3.25, indicating that its share price is 225% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and recommmendations for Information Analysis and SOPHiA GENETICS, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Information Analysis | 0 | 0 | 0 | 0 | 0.00 |
| SOPHiA GENETICS | 1 | 1 | 3 | 0 | 2.40 |
SOPHiA GENETICS has a consensus price target of $10.00, indicating a potential upside of 20.77%. Given SOPHiA GENETICS’s stronger consensus rating and higher possible upside, analysts plainly believe SOPHiA GENETICS is more favorable than Information Analysis.
Summary
Information Analysis beats SOPHiA GENETICS on 8 of the 13 factors compared between the two stocks.
About Information Analysis
Information Analysis, Inc. provides information technology services. The firm engages in the business of modernizing client information systems, developing and maintaining information technology systems, and performing consulting services to government and commercial organizations. It specializes in legacy systems modernization, ebusiness solutions, enterprise portals, system migration and re-hosting services, and enterprise application integration. The company was founded by Sandor Rosenberg in 1979 and is headquartered in Fairfax, VA.
About SOPHiA GENETICS
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
Receive News & Ratings for Information Analysis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Information Analysis and related companies with MarketBeat.com's FREE daily email newsletter.
